Alx Oncology Holdings (ALXO) Non-Current Deffered Revenue (2019)
Alx Oncology Holdings (ALXO) posted Non-Current Deffered Revenue of $135000.0 for Q4 2019.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) Non-Current Deffered Revenue (2019) Analysis & Trends
Alx Oncology Holdings has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $135000.0 in Q4 2019.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $135000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $135000.0 (changed N/A YoY) and the FY2019 annual result came in at $135000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue held at $135000.0 in Q4 2019 per ALXO's latest filing.
- Over five years, Non-Current Deffered Revenue peaked at $135000.0 in Q4 2019 and troughed at $135000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Alx Oncology Holdings | 273.99 Mn | 273.99 Mn | - | - |